Advertisement

Im Focus Onkologie

, Volume 21, Issue 10, pp 44–51 | Cite as

Hoffnung auf Heilbarkeit

Modernes Management der chronischen myeloischen Leukämie*

  • Thomas Ernst
  • Ellen Obstfelder
  • Andreas Hochhaus
Hämatologie Zertifizierte Fortbildung
  • 60 Downloads

Zusammenfassung

Lang andauernde, behandlungsfreie Remissionen bei einer steigenden Patientenzahl verstärken die Hoffnung auf eine Heilbarkeit der chronischen myeloischen Leukämie (CML). Entscheidend ist ein konsequentes zytogenetisches und molekulares Follow-up der CML-Patienten mit standardisierten Methoden, um den Remissionsstatus regelmäßig zu überprüfen.

Literatur

  1. 1.
    Hehlmann R et al. Chronic myeloid leukaemia. Lancet. 2007;370(9584): 342–50CrossRefPubMedGoogle Scholar
  2. 2.
    Pfirrmann M et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56CrossRefPubMedGoogle Scholar
  3. 3.
    Hochhaus A et al. Long-term outcomes of imatinib treatment for CML. N Engl J Med. 2017;376(10):917–27CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Eskazan AE et al. Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec. Clin Lymphoma Myeloma Leuk. 2017;17(12):804–11CrossRefPubMedGoogle Scholar
  5. 5.
    Weisberg E et al. Second generation inhibitors of bcr-abl for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345–56CrossRefPubMedGoogle Scholar
  6. 6.
    Hochhaus A et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5.year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cortes JE et al. Final 5.year study results of DASISION: the dasatinib versus Imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–40CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    La Rosée P et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013;92(10):1345–50CrossRefPubMedGoogle Scholar
  9. 9.
    Cortes JE et al. Bosutinib versus imatinib for newly diagnosed CML: results from the randomized BFORE trial. J Clin Oncol. 2018;36(3):231–7CrossRefPubMedGoogle Scholar
  10. 10.
    Preudhomme C. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511–21CrossRefPubMedGoogle Scholar
  11. 11.
    Simonsson B et al. Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood. 2011;118(12):3228–35CrossRefPubMedGoogle Scholar
  12. 12.
    Burchert A et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010;28(8):1429–35CrossRefPubMedGoogle Scholar
  13. 13.
    Burchert A et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29(6):1331–5CrossRefPubMedGoogle Scholar
  14. 14.
    Mahon FX et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35CrossRefGoogle Scholar
  15. 15.
    Saussele S et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–57CrossRefGoogle Scholar
  16. 16.
    Schmidt M et al. Molecular defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28(12):2292–9CrossRefPubMedGoogle Scholar
  17. 17.
    Kantarjian HM et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141–5CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    le Coutre PD et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia. 2012;26(6):1189–94CrossRefPubMedGoogle Scholar
  19. 19.
    Giles FJ et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012;26(5):959–62CrossRefPubMedGoogle Scholar
  20. 20.
    Hochhaus A et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200–6CrossRefPubMedGoogle Scholar
  21. 21.
    Apperley JF et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol. 2009;27(21):3472–9CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Cortes J et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109(8):3207–13CrossRefPubMedGoogle Scholar
  23. 23.
    Cortes JE et al. A phase 2 trial of ponatinib in Philadelphia chromosomepositive leukemias. N Engl J Med. 2013;369(19):1783–96CrossRefPubMedGoogle Scholar
  24. 24.
    Lipton JH et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(5):612–21CrossRefPubMedGoogle Scholar
  25. 25.
    Saussele S et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML study IV. Blood. 2010;115(10):1880–5CrossRefPubMedGoogle Scholar
  26. 26.
    Hehlmann R. How I treat CML blast crisis. Blood. 2012;120(12):737–47CrossRefPubMedGoogle Scholar
  27. 27.
    Baccarani M et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cross NC et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172–5CrossRefPubMedGoogle Scholar
  29. 29.
    Hanfstein B et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26(9):2096–102CrossRefPubMedGoogle Scholar
  30. 30.
    Hanfstein B et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014;28(10):1988–92CrossRefPubMedGoogle Scholar
  31. 31.
    Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia. 2004;18(8):1321–31CrossRefPubMedGoogle Scholar
  32. 32.
    Soverini S et al. Bcr-abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208–15CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  • Thomas Ernst
    • 1
  • Ellen Obstfelder
    • 2
  • Andreas Hochhaus
    • 2
  1. 1.Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin IIUniversitätsklinikum JenaJenaDeutschland
  2. 2.

Personalised recommendations